STERIS plc (NYSE:STE) Q2 2022 Earnings Conference Call November 3, 2021 10:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and CFO Dan Carestio – President and CEO Conference Call Participants Matthew Mishan – KeyBanc Dave Turkaly – JMP Securities Chris Cooley – Stephens Mike Matson – Needham and Co Michael Polark – Baird Operator Good morning and welcome to the STERIS, PLC Second Quarter, 2022 Conference Call. All participants will be in listen-only mode. ...

STERIS plc (NYSE:STE) Q1 2022 Earnings Conference Call August 10, 2021 10:00 AM ET Company Participants Julie Winter - Vice President, Investor Relations Dan Carestio - President and Chief Executive Officer Mike Tokich - Senior Vice President and Chief Financial Officer Conference Call Participants Matthew Mishan - KeyBanc Mike Matson - Needham & Company Michael Polark - Baird Operator Good morning, everyone and welcome to the STERIS plc First Quarter 2022 Conference Call. [Operator Instructions] Please als ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-38848 STERIS plc (Exact name of registrant as specified in its charter) Ireland 98-1455064 (St ...

United States Securities and Exchange Commission Washington, D. C. 20549 ________________________________________________ FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 STERIS plc (Exact name of registrant as specified in its charter) Ireland 98-1455064 (State or other jurisdiction of incorporation or organization) ...

STERIS plc (NYSE:STE) Q4 2021 Earnings Conference Call May 19, 2021 11:00 AM ET Company Participants Julie Winter - IR Mike Tokich - SVP and CFO Walt Rosebrough - President and CEO Dan Carestio - SVP and COO Conference Call Participants Dave Turkaly - JMP Securities Matthew Mishan - KeyBanc Capital Markets Mike Matson - Needham & Company Chris Cooley - Stephens Inc. Michael Polark - Robert W. Baird Operator Good morning, everyone and welcome to the STERIS plc Fourth Quarter 2021 Conference Call. All partici ...

Cantel Medical Corp. (CMD) Q2 2021 Earnings Conference Call March 9, 2021 8:30 AM ET Company Participants Ryan Lada - VP, Investor Relations George Fotiades - Chief Executive Officer Charles Diker - Chairman Shaun Blakeman - Senior Vice President and Chief Financial Officer Peter Clifford - President and Chief Operating Officer Seth Yellin - Executive Vice President, Strategy and Corporate Development Brian Capone - SVP, Corporate Controller and Chief Accounting Officer Conference Call Participants Matt Mis ...

NYSE:CM N 2nd Quarter FY21 Earnings Call March 09, 2021 Forward Looking Statements 2 This press release contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forwardlooking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, es ...

For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 353 1 232 2000 For the transition period from _______ to _______ Commission File Number 001-38848 STERIS plc (Exact name of registrant as specified in its charter) Ire ...

Financial Data and Key Metrics Changes - Constant currency organic revenue increased by 1.4%, driven by 130 basis points of favorable price and 10 basis points of organic volume growth [7] - Gross margin improved by 110 basis points to 44.2%, benefiting from productivity, price, and acquisitions [7] - EBIT margin increased by 250 basis points to 23.6% of revenue, primarily due to higher gross margin and lower operating expenses [7] - Net income grew by 20% to $149.2 million, with earnings per diluted share increasing to $1.73 from $1.45 in the prior year [8] - Free cash flow for the first nine months was strong at $337.7 million, an increase of almost $100 million over the same period last year [8] Business Line Data and Key Metrics Changes - Constant currency organic revenue in the third quarter grew by 1%, driven by double-digit growth in the AST segment, offset by flat to slightly down revenue in life sciences and healthcare [12] - Life sciences revenue was flat, with mid-single-digit growth in consumables and services, but a decline in capital equipment shipments [13] - Healthcare benefited from the addition of Key Surgical, contributing approximately $15 million to healthcare consumable revenue [14] Market Data and Key Metrics Changes - The healthcare capital equipment segment achieved a record order month, resulting in a backlog greater than pre-pandemic levels [11] - Demand for COVID-related single-use products and components used in vaccine manufacturing positively impacted the AST segment [12] Company Strategy and Development Direction - The company is focused on evaluating opportunities to permanently reduce expenses learned during the pandemic [15] - Integration efforts for Key Surgical are ongoing, with high expectations for future performance [14] - The company is preparing for the acquisition of Cantel Medical, with confidence in the integration process [17] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the fourth quarter and the start of the new fiscal year, noting that risks appear to have declined [15] - The company anticipates a return to normalcy in capital equipment shipments, with expectations for sustained high demand for consumables [16] - Management emphasized the importance of capturing additional opportunities and expressed confidence in the company's future [23] Other Important Information - Walter Rosebrough announced plans to step down as CEO at the end of July, with Dan Carestio set to succeed him [18] - The company has a strong balance sheet, with a leverage ratio below 2 times and a cash position of $253 million [8] Q&A Session Summary Question: Timeline for leadership transition and strategic deals - Walter Rosebrough explained that the timing for his transition is optimal as the company is well-positioned for future success [27] Question: Performance of Key Surgical - Walter noted that the integration of Key Surgical is on track, with performance exceeding initial expectations [28] Question: Succession planning and integration of Cantel - Dan Carestio confirmed that he and Mike Tokich have led the diligence efforts for the Cantel acquisition and are confident in the integration process [37] Question: Sustainability of AST margins - Dan Carestio indicated that while there are benefits from COVID-related demand, core medical device customers are still experiencing suppressed demand [41] Question: Free cash flow expectations - Michael Tokich cautioned that while free cash flow has improved, future acquisitions may require significant cash expenditures [53] Question: Impact of accounting changes on backlog - Dan Carestio clarified that an accounting change earlier in the year affected revenue recognition, impacting the backlog comparison [64] Question: Capital orders and pent-up demand - Dan Carestio acknowledged that there is some pent-up demand from deferred projects during the pandemic [73] Question: COVID-19 incremental costs in adjusted EPS - Michael Tokich explained that costs related to furloughed employees and enhanced cleaning protocols are captured as COVID incremental costs [76]

NYSE:CM N 1st Quarter FY21 Earnings Call December 8th, 2020 Forward Looking Statements 2 This press release contains "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forwardlooking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations ...